Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Loading...
Loading...
  • Edwards Lifesciences Corp EW posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57.
  • Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion.
  • Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's average selling price and market position were stable. 
  • Related: FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery.
  • U.S. TAVR sales grew approximately 10%, and adoption was broad-based across hospitals. 
  • TAVR sales outside the U.S. grew about 20% Y/Y.
  • EW held cash and equivalents of $1.5 billion as of March 31, 2022.
  • Guidance: Edwards Lifesciences reaffirmed its FY22 projection of adjusted EPS of $2.50 - $2.65 (consensus of $2.55) and reiterated its top-line outlook of $5.5 billion - $6.0 billion (consensus $5.76 billion).
  • For Q2 FY22, Edwards Lifesciences expects revenue of $1.36 billion - $1.44 billion (consensus $1.46 billion) and adjusted EPS of $0.61 - $0.69 (consensus $0.65).
  • Analyst Reaction: SVB Leerink analyst Danielle Antalffy maintained an Outperform but lowered the price target from $145 to $138.
  • RBC Capital analyst Shagun Singh maintained an Outperform and lowered the price target from $142 to $135.
  • Raymond James analyst Jayson Bedford maintained an Outperform and reduced the price target from $126 to $124.
  • Price Action: EW shares traded 3.67% lower at $112.00 during pre-market trading on Wednesday.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsGuidanceHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...